OSAGRAND

This brand name is authorized in Lithuania, Poland, Romania.

Active ingredients

The drug OSAGRAND contains one active pharmaceutical ingredient (API):

1	Ibandronic acid UNII UMD7G2653W - IBANDRONIC ACID
	Ibandronic acid belongs to the bisphosphonate group of compounds which act specifically on bone. Their selective action on bone tissue is based on the high affinity of bisphosphonates for bone mineral. Bisphosphonates act by inhibiting osteoclast activity, although the precise mechanism is still not clear. In vivo, ibandronic acid prevents experimentally-induced bone destruction caused by cessation of gonadal function, retinoids, tumours or tumour extracts.
	Read more about Ibandronic acid

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M05BA06	Ibandronic acid	M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BA Bisphosphonates
Discover more medicines within M05BA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1054125, 1063897
PL	Rejestru Produktów Leczniczych	100266953, 100266960
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W57484001, W57484002, W57485001, W57485002, W57485003, W57485004, W57485005, W57485006